113 related articles for article (PubMed ID: 26956669)
21. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract][Full Text] [Related]
22. Cell cycle arrest and apoptosis are early events in radiosensitization of EWS::FLI1
Lin MY; Damron TA; Horton JA
Int J Radiat Biol; 2023; 99(10):1570-1583. PubMed ID: 36913323
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic targeting of the PLK1-PRC1-axis triggers cell death in genomically silent childhood cancer.
Li J; Ohmura S; Marchetto A; Orth MF; Imle R; Dallmayer M; Musa J; Knott MML; Hölting TLB; Stein S; Funk CM; Sastre A; Alonso J; Bestvater F; Kasan M; Romero-Pérez L; Hartmann W; Ranft A; Banito A; Dirksen U; Kirchner T; Cidre-Aranaz F; Grünewald TGP
Nat Commun; 2021 Sep; 12(1):5356. PubMed ID: 34531368
[TBL] [Abstract][Full Text] [Related]
24. Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.
Yeung C; Gibson AE; Issaq SH; Oshima N; Baumgart JT; Edessa LD; Rai G; Urban DJ; Johnson MS; Benavides GA; Squadrito GL; Yohe ME; Lei H; Eldridge S; Hamre J; Dowdy T; Ruiz-Rodado V; Lita A; Mendoza A; Shern JF; Larion M; Helman LJ; Stott GM; Krishna MC; Hall MD; Darley-Usmar V; Neckers LM; Heske CM
Cancer Res; 2019 Oct; 79(19):5060-5073. PubMed ID: 31431459
[TBL] [Abstract][Full Text] [Related]
25. Ganglioside SSEA-4 in Ewing sarcoma marks a tumor cell population with aggressive features and is a potential cell-surface immune target.
Jamitzky S; Altvater B; Krekeler C; Hoen L; Brandes C; Ebbinghaus J; Richter L; Kosel L; Ochs L; Farwick N; Urban K; Kluge L; Bücker L; Görlich D; Johnston ICD; Pfeifer R; Hartmann W; Rossig C; Kailayangiri S
Sci Rep; 2024 May; 14(1):11935. PubMed ID: 38789477
[TBL] [Abstract][Full Text] [Related]
26. Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers.
Tsafou K; Katschnig AM; Radic-Sarikas B; Mutz CN; Iljin K; Schwentner R; Kauer MO; Mühlbacher K; Aryee DNT; Westergaard D; Haapa-Paananen S; Fey V; Superti-Furga G; Toretsky J; Brunak S; Kovar H
Oncotarget; 2018 Jul; 9(57):31018-31031. PubMed ID: 30123424
[TBL] [Abstract][Full Text] [Related]
27. EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis.
Chakraborty S; Bhat AM; Mushtaq I; Luan H; Kalluchi A; Mirza S; Storck MD; Chaturvedi N; Lopez-Guerrero JA; Llombart-Bosch A; Machado I; Scotlandi K; Meza JL; Ghosal G; Coulter DW; Jordan Rowley M; Band V; Mohapatra BC; Band H
Commun Biol; 2023 Jul; 6(1):758. PubMed ID: 37474760
[TBL] [Abstract][Full Text] [Related]
28. Modeling Ewing Sarcoma Lung Metastasis.
Dasgupta A; Kurenbekova L; Patel TD; Rajapakshe K; Ghosal G; Nirala B; Coarfa C; Yustein J
Curr Protoc; 2023 Feb; 3(2):e670. PubMed ID: 36799651
[TBL] [Abstract][Full Text] [Related]
29. Lurbinectedin Inhibits the EWS-WT1 Transcription Factor in Desmoplastic Small Round Cell Tumor.
Gedminas JM; Kaufman R; Boguslawski EA; Gross AC; Adams M; Beddows I; Kitchen-Goosen SM; Roberts RD; Grohar PJ
Mol Cancer Ther; 2022 Aug; 21(8):1296-1305. PubMed ID: 35657345
[TBL] [Abstract][Full Text] [Related]
30. Identification of nuclear export inhibitors with potent anticancer activity in vivo.
Mutka SC; Yang WQ; Dong SD; Ward SL; Craig DA; Timmermans PB; Murli S
Cancer Res; 2009 Jan; 69(2):510-7. PubMed ID: 19147564
[TBL] [Abstract][Full Text] [Related]
31. Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development.
Li H; Watford W; Li C; Parmelee A; Bryant MA; Deng C; O'Shea J; Lee SB
J Clin Invest; 2007 May; 117(5):1314-23. PubMed ID: 17415412
[TBL] [Abstract][Full Text] [Related]
32. Ewing sarcoma gene Ews regulates hematopoietic stem cell senescence.
Cho J; Shen H; Yu H; Li H; Cheng T; Lee SB; Lee BC
Blood; 2011 Jan; 117(4):1156-66. PubMed ID: 21030557
[TBL] [Abstract][Full Text] [Related]
33. CD99 Modulates the Proteomic Landscape of Ewing Sarcoma Cells and Related Extracellular Vesicles.
De Feo A; Manfredi M; Mancarella C; Maqueda JJ; De Giorgis V; Pignochino Y; Sciandra M; Cristalli C; Donadelli M; Scotlandi K
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338867
[TBL] [Abstract][Full Text] [Related]
34. A targeted combinatorial therapy for Ewing's sarcoma.
Sabei FY; Taratula O; Albarqi HA; Al-Fatease AM; Moses AS; Demessie AA; Park Y; Vogel WK; Esfandiari Nazzaro E; Davare MA; Alani A; Leid M; Taratula O
Nanomedicine; 2021 Oct; 37():102446. PubMed ID: 34303840
[TBL] [Abstract][Full Text] [Related]
35. Targeting EYA3 in Ewing Sarcoma Retards Tumor Growth and Angiogenesis.
Wang Y; Pandey RN; Roychoudhury K; Milewski D; Kalin TV; Szabo S; Pressey JG; Hegde RS
Mol Cancer Ther; 2021 May; 20(5):803-815. PubMed ID: 33649104
[No Abstract] [Full Text] [Related]
36. Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages.
Manara MC; Manferdini C; Cristalli C; Carrabotta M; Santi S; De Feo A; Caldoni G; Pasello M; Landuzzi L; Lollini PL; Salamanna F; Dominici S; Fiori V; Magnani M; Lisignoli G; Scotlandi K
Cancer Immunol Res; 2024 Feb; 12(2):247-260. PubMed ID: 38051221
[TBL] [Abstract][Full Text] [Related]
37. EHD1-dependent traffic of IGF-1 receptor to the cell surface is essential for Ewing sarcoma tumorigenesis and metastasis.
Chakraborty S; Bhat AM; Mushtaq I; Luan H; Kalluchi A; Mirza S; Storck MD; Chaturvedi N; Lopez-Guerrero JA; Llombart-Bosch A; Machado I; Scotlandi K; Meza JL; Ghosal G; Coulter DW; Rowley JM; Band V; Mohapatra BC; Band H
bioRxiv; 2023 Mar; ():. PubMed ID: 36711452
[TBL] [Abstract][Full Text] [Related]
38. Cooperation of cancer drivers with regulatory germline variants shapes clinical outcomes.
Musa J; Cidre-Aranaz F; Aynaud MM; Orth MF; Knott MML; Mirabeau O; Mazor G; Varon M; Hölting TLB; Grossetête S; Gartlgruber M; Surdez D; Gerke JS; Ohmura S; Marchetto A; Dallmayer M; Baldauf MC; Stein S; Sannino G; Li J; Romero-Pérez L; Westermann F; Hartmann W; Dirksen U; Gymrek M; Anderson ND; Shlien A; Rotblat B; Kirchner T; Delattre O; Grünewald TGP
Nat Commun; 2019 Sep; 10(1):4128. PubMed ID: 31511524
[TBL] [Abstract][Full Text] [Related]
39. Non-chemotherapy adjuvant agents in TP53 mutant Ewing sarcoma.
Kim JA; Crawford KA; Spada PA; Martin LR; Zhang J; Wong R; Reid JM; Stewart CF; Frank TM; Liu Q; Michalek JE; Keller C
Sci Rep; 2023 Sep; 13(1):14360. PubMed ID: 37658148
[TBL] [Abstract][Full Text] [Related]
40. Enhancing standard of care chemotherapy efficacy using DNA-dependent protein kinase (DNA-PK) inhibition in preclinical models of Ewing sarcoma.
Collins VJ; Ludwig KR; Nelson AE; Sundara Rajan S; Yeung C; Vulikh K; Isanogle KA; Mendoza A; Difilippantonio S; Karim BO; Caplen NJ; Heske CM
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38657228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
